References: Enterobacterales (including E. coli and K. pneumoniae bloodstream infections), including sepsis and septic shock

  • Abdul-Aziz MH, Hammond NE, Brett SJ, Cotta MO, De Waele JJ, Devaux A, et al. Prolonged vs Intermittent Infusions of beta-Lactam Antibiotics in Adults With Sepsis or Septic Shock: A Systematic Review and Meta-Analysis. JAMA 2024;332(8):638-48. https://www.ncbi.nlm.nih.gov/pubmed/38864162
  • Australian Commission on Safety and Quality in Health Care (ACSQHC). AURA 2023: Fifth Australian report on antimicrobial use and resistance in human health. Sydney: Australian Commission on Safety and Quality in Health Care (ACSQHC),; 2023. Updated 16 Nov 2023. Accessed 16 Nov 2023. https://www.safetyandquality.gov.au/our-work/antimicrobial-resistance/antimicrobial-use-and-resistance-australia-aura/aura-2023-fifth-australian-report-antimicrobial-use-and-resistance-human-health
  • Balance Investigators, for the Canadian Critical Care Trials Group the Association of Medical Microbiology, Infectious Disease Canada Clinical Research Network, the Australian New Zealand Intensive Care Society Clinical Trials Group, the Australasian Society for Infectious Diseases Clinical Research Network, Daneman N, et al. Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections. N Engl J Med 2024. https://www.ncbi.nlm.nih.gov/pubmed/39565030
  • Dulhunty JM, Brett SJ, De Waele JJ, Rajbhandari D, Billot L, Cotta MO, et al. Continuous vs Intermittent beta-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial. JAMA 2024;332(8):629-37. https://www.ncbi.nlm.nih.gov/pubmed/38864155
  • Harris PNA, Tambyah PA, Lye DC, Mo Y, Lee TH, Yilmaz M, et al. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial. JAMA 2018;320(10):984-94. https://www.ncbi.nlm.nih.gov/pubmed/30208454
  • McMullan BJ, Andresen D, Blyth CC, Avent ML, Bowen AC, Britton PN, et al. Antibiotic duration and timing of the switch from intravenous to oral route for bacterial infections in children: systematic review and guidelines. Lancet Infect Dis 2016;16(8):e139-52. https://www.ncbi.nlm.nih.gov/pubmed/27321363
  • Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia: A Noninferiority Randomized Controlled Trial. Clin Infect Dis 2019;69(7):1091-8. https://www.ncbi.nlm.nih.gov/pubmed/30535100